Scott M. Wilhelm

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Medicine, Oncology, Pharmacology +17

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

Li Liu, Yichen Cao, Charles Chen et al. · Cancer Research · 2006 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism

Scott M. Wilhelm, Tracy Wang, Daniel T. Ruan et al. · JAMA Surgery · 2016 · 1.3K citations

Medicine, Surgery, Calcium Homeostasis +16

BAY 43-9006 Inhibition of Oncogenic RET Mutants

Francesca Carlomagno, Suresh Anaganti, Teresa Guida et al. · JNCI Journal of the National Cancer Institute · 2006 · 471 citations · Full text

Medicine, Oncology, Pharmacology +17